Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04113382 · ClinicalTrials.gov registry record · Phase 1
Study Assessing CLENPIQ as Bowel Preparation for Pediatric Colonoscopy
A Phase 1 study of Bowel Preparation, sponsored by Ferring Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 5
- Study locations
NCT04113382 is a Phase 1 study of Bowel Preparation that is actively recruiting participants, run by Ferring Pharmaceuticals. The registered enrollment target is 30 participants, below the 1,050-participant average among 3 other Bowel Preparation trials with a reported enrollment target (97% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT04113382, a Phase 1 study of Bowel Preparation, is actively recruiting participants, sponsored by Ferring Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 5
- Study locations
Study Summary
Bowel preparation for pediatric colonoscopy.
Conditions Studied
Interventions
- DRUG CLENPIQ
- DRUG MIRALAX
Study Locations (5)
Maryland
- Ferring Investigational Site - Baltimore
- Ferring Investigational Site - Baltimore
Alabama
- Ferring Investigational Site - Mobile
California
- Ferring Investigational Site - San Diego
New York
- Ferring Investigational Site - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-06-23 |
| Est. Completion | 2026-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04113382
The ClinicalTrials.gov registry entry for NCT04113382 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,050-participant average among 3 other Bowel Preparation trials with a reported enrollment target (97% lower). The listed sponsor is Ferring Pharmaceuticals, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bowel Preparation appearing as the primary indexed condition, and to 2 interventions - of which CLENPIQ is the first listed.
NCT04113382 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Maryland, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT04113382 about?
NCT04113382 is a clinical study titled "Study Assessing CLENPIQ as Bowel Preparation for Pediatric Colonoscopy". Bowel preparation for pediatric colonoscopy.
What is the current status of trial NCT04113382?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2022-06-23. Estimated completion is 2026-03.
What conditions does trial NCT04113382 study?
This clinical trial studies the following conditions: Bowel Preparation.
What interventions are being tested in trial NCT04113382?
The interventions under investigation include: CLENPIQ (DRUG), MIRALAX (DRUG).
Who is sponsoring clinical trial NCT04113382?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04113382 being conducted?
This trial has 5 study locations across Alabama, California, Maryland, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bowel Preparation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.